Phase 1/II, Safety and Immunogenicity Study of a Recombinant Protein Tuberculosis Vaccine (AERAS-404) in BCG-Primed Infants.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 31 Jan 2017
At a glance
- Drugs H4IC (Primary) ; Vaccines
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors Aeras
- 23 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Feb 2018.
- 23 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 23 Jan 2017 Status changed from recruiting to active, no longer recruiting.